152 related articles for article (PubMed ID: 31212875)
1. Single-Case Study of Appetite Control in Prader-Willi Syndrome, Over 12-Years by the Indian Extract
Griggs J
Genes (Basel); 2019 Jun; 10(6):. PubMed ID: 31212875
[TBL] [Abstract][Full Text] [Related]
2. Caralluma fimbriata extract activity involves the 5-HT2c receptor in PWS Snord116 deletion mouse model.
Griggs JL; Mathai ML; Sinnayah P
Brain Behav; 2018 Dec; 8(12):e01102. PubMed ID: 30353709
[TBL] [Abstract][Full Text] [Related]
3. Caralluma Fimbriata Supplementation Improves the Appetite Behavior of Children and Adolescents with Prader-Willi Syndrome.
Griggs JL; Su XQ; Mathai ML
N Am J Med Sci; 2015 Nov; 7(11):509-16. PubMed ID: 26713299
[TBL] [Abstract][Full Text] [Related]
4. The effect of an orally-dosed Caralluma Fimbriata extract on appetite control and body composition in overweight adults.
Rao A; Briskey D; Dos Reis C; Mallard AR
Sci Rep; 2021 Mar; 11(1):6791. PubMed ID: 33762661
[TBL] [Abstract][Full Text] [Related]
5. The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.
Jayawardena R; Francis TV; Abhayaratna S; Ranasinghe P
BMC Complement Med Ther; 2021 Nov; 21(1):279. PubMed ID: 34758791
[TBL] [Abstract][Full Text] [Related]
6. Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.
Kuppens RJ; Diène G; Bakker NE; Molinas C; Faye S; Nicolino M; Bernoux D; Delhanty PJ; van der Lely AJ; Allas S; Julien M; Delale T; Tauber M; Hokken-Koelega AC
Endocrine; 2015 Dec; 50(3):633-42. PubMed ID: 25989955
[TBL] [Abstract][Full Text] [Related]
7. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
Goldstone AP; Holland AJ; Butler JV; Whittington JE
Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
[TBL] [Abstract][Full Text] [Related]
8. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
[TBL] [Abstract][Full Text] [Related]
9. Phytochemical analysis and effects on ingestive behaviour of a Caralluma fimbriata extract.
Vitalone A; Di Sotto A; Mammola CL; Heyn R; Miglietta S; Mariani P; Sciubba F; Passarelli F; Nativio P; Mazzanti G
Food Chem Toxicol; 2017 Oct; 108(Pt A):63-73. PubMed ID: 28713048
[TBL] [Abstract][Full Text] [Related]
10. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome.
McCarthy JM; McCann-Crosby BM; Rech ME; Yin J; Chen CA; Ali MA; Nguyen HN; Miller JL; Schaaf CP
J Med Genet; 2018 May; 55(5):307-315. PubMed ID: 29496979
[TBL] [Abstract][Full Text] [Related]
11. Prader-Willi syndrome: From genetics to behaviour, with special focus on appetite treatments.
Griggs JL; Sinnayah P; Mathai ML
Neurosci Biobehav Rev; 2015 Dec; 59():155-72. PubMed ID: 26475993
[TBL] [Abstract][Full Text] [Related]
12. Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches.
Muscogiuri G; Barrea L; Faggiano F; Maiorino MI; Parrillo M; Pugliese G; Ruggeri RM; Scarano E; Savastano S; Colao A;
J Endocrinol Invest; 2021 Oct; 44(10):2057-2070. PubMed ID: 33891302
[TBL] [Abstract][Full Text] [Related]
13. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of obesity in Prader-Willi syndrome.
Khan MJ; Gerasimidis K; Edwards CA; Shaikh MG
Pediatr Obes; 2018 Jan; 13(1):3-13. PubMed ID: 27863129
[TBL] [Abstract][Full Text] [Related]
15. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.
Gunay-Aygun M; Schwartz S; Heeger S; O'Riordan MA; Cassidy SB
Pediatrics; 2001 Nov; 108(5):E92. PubMed ID: 11694676
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
17. Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment.
Palmieri VV; Lonero A; Bocchini S; Cassano G; Convertino A; Corica D; Crinò A; Fattorusso V; Ferraris S; Fintini D; Franzese A; Grugni G; Iughetti L; Lia R; Macchi F; Madeo SF; Matarazzo P; Nosetti L; Osimani S; Pajno R; Patti G; Pellegrin MC; Perri A; Ragusa L; Rutigliano I; Sacco M; Salvatoni A; Scarano E; Stagi S; Tornese G; Trifirò G; Wasniewska M; Fischetto R; Giordano P; Licenziati MR; Delvecchio M;
Growth Horm IGF Res; 2019; 48-49():9-15. PubMed ID: 31487604
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
[TBL] [Abstract][Full Text] [Related]
19. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels.
Purtell L; Sze L; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
Neuropeptides; 2011 Aug; 45(4):301-7. PubMed ID: 21722955
[TBL] [Abstract][Full Text] [Related]
20. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
De Waele K; Ishkanian SL; Bogarin R; Miranda CA; Ghatei MA; Bloom SR; Pacaud D; Chanoine JP
Eur J Endocrinol; 2008 Oct; 159(4):381-8. PubMed ID: 18603572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
